Hepatitis C
Brivanib Does Not Improve Liver Cancer Survival for Treatment-Experienced Patients
- Details
- Category: Liver Cancer/HCC
- Published on Tuesday, 03 January 2012 00:00
Bristol-Meyers Squibb's investigational anti-cancer drug brivanib did not improve overall survival of patients with hepatocellular carcinoma (HCC) who were unable to take or did not respond to sorafenib (Nexavar) in the Phase 3 BRISK-PS trial, the company recently reported. The drug is still being tested in other patients populations.
PegIntron Label Updated to Include Use with New Direct-Acting HCV Agents
- Details
- Category: HCV Treatment
- Published on Tuesday, 27 December 2011 00:00
The U.S. Food and Drug Administration (FDA) last week announced revisions to the product label for pegylated interferon alfa-2b (brand name PegIntron) to incorporate information about its use with the recently approved hepatitis C virus (HCV) protease inhibitors boceprevir (Victrelis) and telaprevir (Incivek), as well as use by people with psychiatric conditions.
Merck and Roche to Collaborate on Combination Regimens for Hepatitis C
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 16 December 2011 00:00
Merck this week announced a collaboration with Roche to evaluate combination regimens for chronic hepatitis C virus (HCV) infection containing Merck's approved HCV protease inhibitor boceprevir (Victrelis) and Roche's experimental HCV polymerase inhibitor mericitabine (formerly RO5024048 and RG7128).
AASLD 2011: Fever Signals Responsiveness to Pegylated Interferon for Hepatitis C
- Details
- Category: HCV Treatment
- Published on Tuesday, 27 December 2011 00:00
People who have an increase in body temperature soon after starting interferon-based therapy for chronic hepatitis C virus (HCV) infection are more likely to experience early virological response, according to a presentation at the American Association for the Study of Liver Disease (AASLD) Liver Meeting last month in San Francisco.
Green Tea Component May Help Prevent HCV Re-infection after Liver Transplant
- Details
- Category: HCV Treatment
- Published on Tuesday, 13 December 2011 00:00
An anti-oxidant compound in green tea may inhibit entry of hepatitis C virus (HCV) into liver cells, which could potentially prevent re-infection of the new liver after transplantation, according to a study described in the December 2011 issue of Hepatology.
AASLD 2011: Recombinant Hepatitis C Vaccine TG404 Shows Promise in Phase 2 Trial
- Details
- Category: HCV Treatment
- Published on Tuesday, 20 December 2011 00:00
Transgene's recombinant poxvirus therapeutic hepatitis C virus (HCV) vaccine, TG4040, demonstrated good tolerability and increased the likelihood of viral suppression at 12 weeks when administered with pegylated interferon plus ribavirin, according to data from an international Phase 2 clinical trial reported at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting last month in San Francisco. 
Two New Nucleotide HCV Polymerase Inhibitors Enter Clinical Trials
- Details
- Category: HCV Treatment
- Published on Tuesday, 13 December 2011 00:00
A pair of hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitors, ALS-2200 and ALS-2158, are now entering Phase 1 human trials, according to a recent announcement.
Novel P7 Inhibitor BIT225 Improves Hepatitis C Response, also Inhibits HIV
- Details
- Category: HCV Treatment
- Published on Friday, 16 December 2011 00:00
At the HepDART drug development conference this month researchers presented interim data from a Phase 2 clinical trial showing that a novel direct-acting antiviral known as BIT225 improved the likelihood of virological response at 12 weeks when added to pegylated interferon/ribavirin.
New Hepatitis C NS5A Inhibitor ACH-2928 Shows Potent Antiviral Activity
- Details
- Category: HCV Treatment
- Published on Friday, 09 December 2011 00:00
Achillion's novel once-daily hepatitis C virus (HCV) NS5A inhibitor ACH-2928 was well-tolerated and lowered viral load by more than 3.6 log in a 3-day monotherapy study, the company announced this week. These findings suggest ACH-2928 may be a promising candidate for inclusion in future oral direct-acting antiviral regimens.
More Articles...
- AASLD 2011: High Sustained Response Rates with Danoprevir plus Pegylated Interferon/Ribavirin for HCV
- HCV Polymerase Inhibitor INX-189 Looks Promising in Early Study
- AASLD 2011: Milk Thistle Extract Did Not Improve Liver Inflammation or Quality of Life for Hepatitis C Patients
- AASLD 2011: Daclatasvir with Pegylated Interferon/ Ribavirin Produces High Rates of HCV Suppression
- Companies to Evaluate Daclatasvir plus TMC435 for Hepatitis C
Web Design and Development by